Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 22:9:1080584.
doi: 10.3389/fsurg.2022.1080584. eCollection 2022.

Current treatment strategies for primary upper extremity deep venous thrombosis; a retrospective observational multicenter case series

R J C M F de Kleijn  1 , L Schropp  1 , J Westerink  2 , M Nijkeuter  3 , J van Laanen  4 , J Teijink  5 , C Ünlu  6 , A W F Vos  7 , E S van Hattum  1 , B J Petri  1 , G J de Borst  1
Affiliations

Current treatment strategies for primary upper extremity deep venous thrombosis; a retrospective observational multicenter case series

R J C M F de Kleijn et al. Front Surg. .

Abstract

Introduction: Current treatment strategies for primary upper extremity deep venous thrombosis (pUEDVT) range from conservative treatment with anticoagulation therapy to invasive treatment with thoracic outlet decompression surgery (TOD), frequently combined with catheter directed thrombolysis, percutaneous transluminal angioplasty, or stenting. Due to a lack of large prospective series with uniform data collection or a randomized trial, the optimal treatment strategy is still under debate. We conducted a multicenter observational study to assess the efficacy and safety of both the conservative and invasive treatment strategies for patients with pUEDVT.

Methods: We retrospectively collected data from patients treated in five vascular referral and teaching hospitals in the Netherlands between 2008 and 2019. Patients were divided into a conservative (Group 1), an invasive treatment group (Group 2) and a cross-over group (Group 3) of patients who received surgical treatment after initial conservative therapy. Follow-up consisted of outpatient clinic visits and an electronic survey. Primary outcome was symptom free survival defined as absence of any symptom of the affected arm reported at last follow-up regardless of severity, or extent of functional disability. Secondary outcomes were incidence of bleeding complications, recurrent venous thromboembolism, surgical complications, and reinterventions.

Results: A total of 115 patients were included (group 1 (N = 45), group 2 (N = 53) or group 3 (N = 27). The symptom free survival was 35.6%, 54.7% and 48.1% after a median follow-up of 36, 26 and 22 months in groups 1, 2 and 3 respectively. Incidence of bleeding complications was 8.6%, 3.8% and 18.5% and recurrent thrombosis occurred in 15.6%, 13.2% and 14.8% in groups 1-3 respectively.

Conclusion: In this multicenter retrospective observational cohort analysis the conservative and direct invasive treatments for pUEDVT were deemed safe with low percentages of bleeding complications. Symptom free survival was highest in the direct surgical treatment group but still modest in all subgroups. Perioperative complications were infrequent with no related long term morbidity. Of relevance, pUEDVT patients with confirmed VTOS and recurrent symptoms after conservative treatment may still benefit from TOD surgery. However, symptom free survival of this delayed TOD seems lower than direct surgical treatment and bleeding complications seem to occur more frequently.

Keywords: UEDVT; anticoagulation therapy; first rib resection and scalenectomy; upper extremity deep venous thrombosis; venous thoracic outlet syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Lindblad B, Tengborn L, Bergqvist D. Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg. (1988) 2(3):161–5. 10.1016/s0950-821x(88)80069-0 - DOI - PubMed
    1. Isma N, Svensson PJ, Gottsater A, Lindblad B. Upper extremity deep venous thrombosis in the population-based malmo thrombophilia study (MATS). epidemiology, risk factors, recurrence risk, and mortality. Thromb Res. (2010) 125(6):e335–8. 10.1016/j.thromres.2010.03.005 - DOI - PubMed
    1. Illig KA, Rodriguez-Zoppi E, Bland T, Muftah M, Jospitre E. The incidence of thoracic outlet syndrome. Ann Vasc Surg. (2021) 70(August 2020):263–72. 10.1016/j.avsg.2020.07.029 - DOI - PubMed
    1. Schropp L, de Kleijn RJCMF, Vonken EJ, van Laanen J, Teijink J, Ünlu Ç, et al. Multicenter case series and literature review on durability of stents in the thoracic outlet. J Endovasc Ther an Off J Int Soc Endovasc Spec. (2022), 15266028221081078. 10.1177/15266028221081078. [Epub ahead of print]. - DOI - PubMed
    1. Kahn SR, Elman EA, Bornais C, Blostein M, Wells PS. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost. (2005) 93(3):499–502. 10.1160/TH04-10-0640 - DOI - PubMed

LinkOut - more resources